Fred Alger Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-8,000
Closed -$388K 540
2019
Q3
$388K Sell
8,000
-16,500
-67% -$860K ﹤0.01% 379
2019
Q2
$1.29M Buy
24,500
+2,500
+11% +$144K 0.01% 321
2019
Q1
$1.16M Sell
22,000
-1,000
-4% -$49.1K ﹤0.01% 319
2018
Q4
$944K Buy
23,000
+1,000
+5% +$37.5K ﹤0.01% 322
2018
Q3
$836K Sell
22,000
-9,788
-31% -$434K ﹤0.01% 335
2018
Q2
$1.44M Buy
31,788
+23,788
+297% +$1.08M 0.01% 302
2018
Q1
$386K Buy
+8,000
New +$446K ﹤0.01% 381
2017
Q4
Sell
-3,000
Closed -$93K 605
2017
Q3
$93K Sell
3,000
-2,000
-40% -$56.2K ﹤0.01% 392
2017
Q2
$137K Sell
5,000
-11,000
-69% -$327K ﹤0.01% 396
2017
Q1
$590K Buy
16,000
+4,000
+33% +$101K ﹤0.01% 354
2016
Q4
$173K Sell
12,000
-7,000
-37% -$123K ﹤0.01% 355
2016
Q3
$438K Buy
19,000
+2,000
+12% +$38.1K ﹤0.01% 361
2016
Q2
$282K Buy
+17,000
New +$343K ﹤0.01% 405
2016
Q1
Sell
-16,050
Closed -$519K 615
2015
Q4
$519K Sell
16,050
-1,800
-10% -$77.9K ﹤0.01% 432
2015
Q3
$753K Buy
+17,850
New +$842K ﹤0.01% 403

Other funds holding GBT

Fred Alger Management's GBT Position: Q4 2019 in Review

Fred Alger Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2019, closing a stake of 8,000 shares — an estimated $388K sold.

Fred Alger Management first reported a position in GBT in Q3 2015 and held it in 15 quarters. The position peaked at $1.44M in Q2 2018. 234 funds tracked by Wall St. Rank hold GBT as of Q4 2019.

  • Fred Alger Management reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2019 after selling out during the quarter.
  • Fred Alger Management sold 8,000 Global Blood Therapeutics, Inc. shares in Q4 2019, an estimated $388K.
  • Fred Alger Management first reported a position in Global Blood Therapeutics, Inc. in Q3 2015 and held it in 15 quarters.
  • Fred Alger Management's Global Blood Therapeutics, Inc. position peaked at $1.44M in Q2 2018.
  • 234 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2019.

Based on Fred Alger Management's 13F filing for Q4 2019, filed 14 Feb 2020.